Gordian Capital (Singapore)’s Novo Nordisk NVO Stock Holding History

Gordian Capital (Singapore)’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$735K	Sell	20,000 -2,500	-11%	-$118K	1.23%	24
2025 Q4	$1.14M	Buy	22,500 +9,500	+73%	+$486K	1.58%	27
2025 Q3	$721K	Buy	13,000 +6,500	+100%	+$380K	0.98%	36
2025 Q2	$449K	Hold	6,500	–	–	0.66%	32
2025 Q1	$451K	Hold	6,500	–	–	0.28%	51
2024 Q4	$557K	Buy	6,500 +3,002	+86%	+$325K	0.29%	54
2024 Q3	$417K	Sell	3,498 -3,602	-51%	-$480K	0.16%	64
2024 Q2	$1.01M	Buy	7,100 +2,100	+42%	+$278K	0.58%	31
2024 Q1	$642K	Buy	5,000 +2,000	+67%	+$238K	0.48%	30
2023 Q4	$310K	Buy	+3,000	New	+$297K	0.28%	35
2022 Q2	–	Sell	-1,700	Closed	-$85K	–	143
2022 Q1	$85K	Hold	1,700	–	–	0.07%	63
2021 Q4	$96K	Buy	+1,700	New	+$92.1K	0.08%	74

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Gordian Capital (Singapore)'s NVO Position: Q1 2026 in Review

Gordian Capital (Singapore) reduced its Novo Nordisk (NVO) stake by 11% in Q1 2026, selling an estimated $118K and leaving 20,000 shares worth $735K. The position accounts for 1.23% of the portfolio, ranked #24.

Gordian Capital (Singapore) first reported a position in NVO in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.14M in Q4 2025. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Gordian Capital (Singapore) held 20,000 shares of Novo Nordisk worth $735K as of Q1 2026.
Gordian Capital (Singapore) sold 2,500 Novo Nordisk shares in Q1 2026, an estimated $118K.
Novo Nordisk made up 1.23% of Gordian Capital (Singapore)'s portfolio in Q1 2026, its #24 holding.
Gordian Capital (Singapore) first reported a position in Novo Nordisk in Q4 2021 and has held it in 12 quarters since.
Gordian Capital (Singapore)'s Novo Nordisk position peaked at $1.14M in Q4 2025.
1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Gordian Capital (Singapore)'s 13F filing for Q1 2026, filed 13 May 2026.